Rare diseases
Investigational molecules
Locations
1 Main Street Suite 520, 02142-1531, United States
Cullinan Pearl Corp. focuses on non-small cell lung cancer with a specific emphasis on tumors carrying EGFR exon 20 insertion mutations. Its clinical research in this area is centered on patients with advanced disease and treatment-resistant disease patterns.
The sponsor’s oncology activity is directed toward defining clinically relevant outcomes in a molecularly selected lung cancer population.
Cullinan Pearl Corp. runs clinical trials in conditions such as Non-small cell lung cancer recurrent, Non-small cell lung cancer metastatic, among others.
Clinical trials registered by this sponsor – none is enrolling right now.
ItalyIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
